|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0014520,
umls-concept:C0017262,
umls-concept:C0017337,
umls-concept:C0086418,
umls-concept:C0087111,
umls-concept:C0178602,
umls-concept:C0185117,
umls-concept:C0205307,
umls-concept:C0332237,
umls-concept:C0913459,
umls-concept:C1413863,
umls-concept:C1522168,
umls-concept:C1999216,
umls-concept:C2606129,
umls-concept:C2911684
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2009-1-9
|
|
pubmed:abstractText |
An alternative approach to retinoid therapy is to inhibit the cytochrome P450 (CYP)-mediated catabolism of endogenous all-trans retinoic acid in the skin by applying retinoic acid metabolism blocking agents such as talarozole (R115866).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Benzothiazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers,
http://linkedlifedata.com/resource/pubmed/chemical/Cytochrome P-450 Enzyme System,
http://linkedlifedata.com/resource/pubmed/chemical/R 115866,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Retinoic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Retinal Dehydrogenase,
http://linkedlifedata.com/resource/pubmed/chemical/Retinoids,
http://linkedlifedata.com/resource/pubmed/chemical/Triazoles,
http://linkedlifedata.com/resource/pubmed/chemical/cytochrome P-450 CYP26B1,
http://linkedlifedata.com/resource/pubmed/chemical/retinoic acid binding protein II...
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1365-2133
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
160
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
26-36
|
|
pubmed:meshHeading |
pubmed-meshheading:19016711-Administration, Topical,
pubmed-meshheading:19016711-Adolescent,
pubmed-meshheading:19016711-Adult,
pubmed-meshheading:19016711-Analysis of Variance,
pubmed-meshheading:19016711-Benzothiazoles,
pubmed-meshheading:19016711-Biological Markers,
pubmed-meshheading:19016711-Cell Proliferation,
pubmed-meshheading:19016711-Cytochrome P-450 Enzyme System,
pubmed-meshheading:19016711-Dose-Response Relationship, Drug,
pubmed-meshheading:19016711-Double-Blind Method,
pubmed-meshheading:19016711-Epidermis,
pubmed-meshheading:19016711-Female,
pubmed-meshheading:19016711-Gene Expression,
pubmed-meshheading:19016711-Humans,
pubmed-meshheading:19016711-Immunohistochemistry,
pubmed-meshheading:19016711-Male,
pubmed-meshheading:19016711-Middle Aged,
pubmed-meshheading:19016711-RNA, Messenger,
pubmed-meshheading:19016711-Receptors, Retinoic Acid,
pubmed-meshheading:19016711-Retinal Dehydrogenase,
pubmed-meshheading:19016711-Retinoids,
pubmed-meshheading:19016711-Triazoles,
pubmed-meshheading:19016711-Young Adult
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Topical treatment with CYP26 inhibitor talarozole (R115866) dose dependently alters the expression of retinoid-regulated genes in normal human epidermis.
|
|
pubmed:affiliation |
Department of Medical Sciences/Dermatology, Uppsala University, SE-751 85 Uppsala, Sweden.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
